Equities analysts expect Ventas (NYSE:VTR) to report sales of $892.39 million for the current quarter, Zacks reports. Three analysts have issued estimates for Ventas’ earnings, with the lowest sales estimate coming in at $832.27 million and the highest estimate coming in at $931.10 million. Ventas reported sales of $895.49 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 0.3%. The business is expected to announce its next quarterly earnings report on Friday, July 27th.
According to Zacks, analysts expect that Ventas will report full-year sales of $3.57 billion for the current fiscal year, with estimates ranging from $3.35 billion to $3.70 billion. For the next year, analysts forecast that the business will report sales of $3.64 billion per share, with estimates ranging from $3.47 billion to $3.76 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Ventas.
Ventas (NYSE:VTR) last issued its quarterly earnings data on Friday, April 27th. The real estate investment trust reported $0.22 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.01 by ($0.79). The business had revenue of $943.70 million for the quarter, compared to analyst estimates of $874.42 million. Ventas had a return on equity of 5.24% and a net margin of 34.04%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.55 earnings per share.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its position in Ventas by 1.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 113,843 shares of the real estate investment trust’s stock worth $6,832,000 after purchasing an additional 1,777 shares in the last quarter. Hexavest Inc. grew its position in Ventas by 0.9% during the 4th quarter. Hexavest Inc. now owns 1,077,199 shares of the real estate investment trust’s stock worth $64,643,000 after purchasing an additional 10,073 shares in the last quarter. Atria Investments LLC grew its position in Ventas by 40.8% during the 4th quarter. Atria Investments LLC now owns 6,863 shares of the real estate investment trust’s stock worth $412,000 after purchasing an additional 1,989 shares in the last quarter. Gofen & Glossberg LLC IL grew its position in Ventas by 4.4% during the 4th quarter. Gofen & Glossberg LLC IL now owns 34,638 shares of the real estate investment trust’s stock worth $2,079,000 after purchasing an additional 1,466 shares in the last quarter. Finally, Clean Yield Group grew its position in Ventas by 4.1% during the 4th quarter. Clean Yield Group now owns 82,140 shares of the real estate investment trust’s stock worth $4,929,000 after purchasing an additional 3,200 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.
NYSE:VTR traded up $0.13 during midday trading on Monday, hitting $52.50. 1,472,386 shares of the stock were exchanged, compared to its average volume of 2,911,949. Ventas has a one year low of $46.55 and a one year high of $72.36. The stock has a market cap of $18,674.33, a price-to-earnings ratio of 12.59, a PEG ratio of 3.45 and a beta of 0.07. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.14 and a quick ratio of 1.20.
The business also recently declared a quarterly dividend, which was paid on Thursday, April 12th. Shareholders of record on Monday, April 2nd were issued a $0.79 dividend. The ex-dividend date of this dividend was Thursday, March 29th. This represents a $3.16 annualized dividend and a dividend yield of 6.02%. Ventas’s dividend payout ratio is currently 75.96%.
Ventas Company Profile
Ventas, Inc, an S&P 500 company, is a leading real estate investment trust. Its diverse portfolio of more than 1,200 assets in the United States, Canada and the United Kingdom consists of seniors housing communities, medical office buildings, life science and innovation centers, inpatient rehabilitation and long-term acute care facilities, health systems and skilled nursing facilities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ventas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas and related companies with MarketBeat.com's FREE daily email newsletter.